Alan Breier, M.D.

Alan Breier, M.D., was named vice president of Medical and Chief Medical Officer for Eli Lilly and Company in August 2003.  He is a member of the Lilly Research Laboratories Policy Committee and Lilly's Senior Management Council.  He joined Lilly as a LRL Research Fellow in March 1997, the same year he was appointed adjunct professor of psychiatry at Indiana University School of Medicine in Indianapolis. He received a doctor of medicine degree from the University of Cincinnati School of Medicine, and trained in psychiatry at Yale University School of Medicine.  Dr. Breier was Associate Research Professor of Psychiatry at the University of Maryland School of Medicine and Chief, Section on Clinical Studies at the National Institute of Mental Health Intramural Research Program.  In 1997, Dr. Breier began a career at Eli Lilly and Company where he has focused on neuroscience drug development and led the Zyprexa Product Team.  In his current role as Chief Medical Officer, Dr. Breier leads Lilly’s medical organization which annually conducts clinical trials in over 60 countries spanning phase I through phase IV studies.  Dr. Breier has been responsible for sponsoring the Principles of Medical Research which encompasses ethical standards for medical research, and establishing Lilly’s clinical trial registry which is a publicly accessible web based site for posting the initiation and results of clinical trials. Dr. Breier is recipient of several awards including the A.E. Bennett Neuropsychiatric Research Foundation Award and the Joel Elkes International Award.  He is a Fellow of the American College of Neuropsychopharmacolgy and has published over 225 scientific papers.  He is included in Best Doctors in America.